갑상선 질환 치료 시장 규모, 점유율, 동향 및 성장 분석 보고서(2026-2034년)

The Thyroid Gland Disorder Treatment Market size is expected to reach USD 4.01 Billion in 2034 from USD 2.85 Billion (2025) growing at a CAGR of 3.87% during 2026-2034.

The Global Thyroid Gland Disorder Treatment Market is witnessing steady growth due to the rising prevalence of hypothyroidism, hyperthyroidism, and thyroid cancer worldwide. Increasing awareness about early diagnosis and routine screening programs is supporting market expansion. Growing incidences of iodine deficiency and autoimmune disorders such as Hashimoto's thyroiditis and Graves' disease further drive treatment demand. Improved access to healthcare services and availability of generic medications are also contributing to market growth.

Key drivers include the aging population, which is more prone to thyroid dysfunction, and advancements in diagnostic technologies. Pharmaceutical innovations in hormone replacement therapies and targeted cancer treatments enhance treatment outcomes. Rising healthcare expenditure and favorable reimbursement policies in developed nations further stimulate demand. Additionally, increasing adoption of minimally invasive surgical procedures for thyroid disorders supports the market's steady development.

Looking ahead, personalized medicine and biologic therapies are expected to create new growth opportunities. Continuous research in targeted therapies and improved drug formulations will enhance patient compliance and efficacy. Emerging economies are projected to witness higher growth due to improving healthcare infrastructure. As awareness about endocrine health increases globally, the thyroid gland disorder treatment market is likely to expand consistently.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Indication

• Hypothyroidism
• Hyperthyroidism

By Drug

• Levothyroxine
• Liothyronine
• Propylthiouracil
• Imidazole-based Compounds
• Others

By Distribution Channel

• Wholesale Distribution
• Retail Stores
• Online Pharmacy

By Route of Administration

• Oral
• Intravenous
• Others

COMPANIES PROFILED

• AbbVie Inc, Amgen Inc, GlaxoSmithKline plc, Merck KGaA, Viatris Inc, Novartis AG, Pfizer Inc, Takeda Pharmaceutical Company Limited, Elexis Inc, IBSA Institut Biochimique SA IBSA Group
• We can customise the report as per your requirements.

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL THYROID GLAND DISORDER TREATMENT MARKET: BY INDICATION 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Indication
• 4.2. Hypothyroidism Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. Hyperthyroidism Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL THYROID GLAND DISORDER TREATMENT MARKET: BY DRUG 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Drug
• 5.2. Levothyroxine Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. Liothyronine Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.4. Propylthiouracil Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.5. Imidazole-based Compounds Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.6. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL THYROID GLAND DISORDER TREATMENT MARKET: BY DISTRIBUTION CHANNEL 2022-2034 (USD MN)

• 6.1. Market Analysis, Insights and Forecast Distribution Channel
• 6.2. Wholesale Distribution Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.3. Retail Stores Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.4. Online Pharmacy Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL THYROID GLAND DISORDER TREATMENT MARKET: BY ROUTE OF ADMINISTRATION 2022-2034 (USD MN)

• 7.1. Market Analysis, Insights and Forecast Route Of Administration
• 7.2. Oral Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.3. Intravenous Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.4. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 8. GLOBAL THYROID GLAND DISORDER TREATMENT MARKET: BY REGION 2022-2034(USD MN)

• 8.1. Regional Outlook
• 8.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.2.1 By Indication
  • 8.2.2 By Drug
  • 8.2.3 By Distribution Channel
  • 8.2.4 By Route Of Administration
  • 8.2.5 United States
  • 8.2.6 Canada
  • 8.2.7 Mexico
• 8.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.3.1 By Indication
  • 8.3.2 By Drug
  • 8.3.3 By Distribution Channel
  • 8.3.4 By Route Of Administration
  • 8.3.5 United Kingdom
  • 8.3.6 France
  • 8.3.7 Germany
  • 8.3.8 Italy
  • 8.3.9 Russia
  • 8.3.10 Rest Of Europe
• 8.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.4.1 By Indication
  • 8.4.2 By Drug
  • 8.4.3 By Distribution Channel
  • 8.4.4 By Route Of Administration
  • 8.4.5 India
  • 8.4.6 Japan
  • 8.4.7 South Korea
  • 8.4.8 Australia
  • 8.4.9 South East Asia
  • 8.4.10 Rest Of Asia Pacific
• 8.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.5.1 By Indication
  • 8.5.2 By Drug
  • 8.5.3 By Distribution Channel
  • 8.5.4 By Route Of Administration
  • 8.5.5 Brazil
  • 8.5.6 Argentina
  • 8.5.7 Peru
  • 8.5.8 Chile
  • 8.5.9 South East Asia
  • 8.5.10 Rest of Latin America
• 8.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.6.1 By Indication
  • 8.6.2 By Drug
  • 8.6.3 By Distribution Channel
  • 8.6.4 By Route Of Administration
  • 8.6.5 Saudi Arabia
  • 8.6.6 UAE
  • 8.6.7 Israel
  • 8.6.8 South Africa
  • 8.6.9 Rest of the Middle East And Africa

Chapter 9. COMPETITIVE LANDSCAPE

• 9.1. Recent Developments
• 9.2. Company Categorization
• 9.3. Supply Chain & Channel Partners (based on availability)
• 9.4. Market Share & Positioning Analysis (based on availability)
• 9.5. Vendor Landscape (based on availability)
• 9.6. Strategy Mapping

Chapter 10. COMPANY PROFILES OF GLOBAL THYROID GLAND DISORDER TREATMENT INDUSTRY

• 10.1. Top Companies Market Share Analysis
• 10.2. Company Profiles
  • 10.2.1 AbbVie Inc
  • 10.2.2 Amgen Inc
  • 10.2.3 GlaxoSmithKline Plc
  • 10.2.4 Merck KGaA
  • 10.2.5 Viatris Inc
  • 10.2.6 Novartis AG
  • 10.2.7 Pfizer Inc
  • 10.2.8 Takeda Pharmaceutical Company Limited
  • 10.2.9 Elexis Inc
  • 10.2.10 IBSA Institut Biochimique SA (IBSA Group)